Clinical Trial

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Study acronym: PRELUDE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed on Pembrolizumab as their prior therapy in the adjuvant RCC setting.
Trial Details
NCT Number NCT07460206
Lead Sponsor Gruppo Oncologico Italiano di Ricerca Clinica
Conditions ccRCC
Enrollment 108 participants
Start Date 2026-08
Primary Completion 2031-08 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-10